Overall, given the progress to date and the breadth of preclinical and clinical research currently underway to target this key oncogenic driver in GC, FGFR2 inhibitors are likely to have a meaningful clinical impact in patients with FGFR2-driven GC in the future. Here, FGFR2 is linked to gastric cancer.